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Although considerable progress has been made in trauma resuscitation, traumatic hemorrhage and coagulopathy remain major causes of mortality.1,2 
Morbidity and mortality in patients with trauma-induced 
coagulopathy is up to 4 times greater than in patients without 
trauma-induced coagulopathy.3 The so-called “lethal triad” 
of coagulopathy, acidosis, and hypothermia starts early after 
traumatic injury and is associated with increased mortality.4–6 
In addition, hemodilution, shock with hypoperfusion of tis-
sues, and inflammation also may play a role.7–9 As a result of 
these early derangements, one-third of patients arriving in the 
emergency department (ED) present with coagulopathy.10–12
The identification and the early treatment or avoidance 
of coagulopathy are thus of major interest and should be 
initiated in the prehospital setting because the mean time 
from injury to arrival in the ED has been described in the 
literature as approximately 75 minutes in Europe and North 
America, which exceeds the “golden hour.”11–13 Although 
Floccard et al.14 studied conventional variables of coagula-
tion at the trauma scene, no comprehensive study on con-
ventional, plasma-based coagulation variables, including 
coagulation factor XIII (FXIII) and whole blood coagulation 
measures such as rotational thromboelastometry (ROTEM® 
delta; TEM® International GmbH, Munich, Germany), 
has been performed. In this study, we investigated the ini-
tial changes and the course of conventional, plasma-based 
coagulation variables, including FXIII, ROTEM, variables of 
blood gas analysis, protein S, and protein C activity, from 
on-scene to the ED in traumatized patients with an NACA 
score ≥III. (NACA score is a scoring system of the severity 
in cases of medical emergencies such as injuries, diseases, or 
poisonings. It was developed from the National Advisory 
Committee for Aeronautics for accidents in aviation.)
METHODS
The protocol was approved by the local ethics committee 
(Kantonale Ethikkommission Zurich, Switzerland, study 
number StV 21–2008) including the fact that subjects were 
exempted from consent because the first blood sample was 
drawn under conditions in which patients could not give 
informed consent.15 Patients or their relatives (in case of 
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death) were contacted once they were medically stabilized 
to get delayed consent. If consent was refused, the patient 
and all data were removed from the study.
This single-center, prospective, observational study was 
conducted from April 2009 to October 2012 at the University 
Hospital Zurich in collaboration with the emergency medi-
cal services (EMS) of the city of Zurich, Switzerland (Schutz 
und Rettung Stadt Zürich).
To be eligible for this study, patients had to be older than 
18 years of age, sustain blunt or penetrating trauma, have an 
NACA score of ≥III, and the time between trauma and the 
first blood sample had to be <30 minutes. An NACA score 
of III indicates a moderate-to-severe but not life-threatening 
disorder that requires stationary treatment and often emer-
gency medical measures on-scene (e.g., femur fracture, mild 
stroke, smoke inhalation). An NACA score of IV is a seri-
ous event in which rapid development of a life-threatening 
condition cannot be excluded and emergency medical care 
is required. Exclusion criteria were cardiopulmonary resus-
citation, death on site or during transportation, and admin-
istration of any type of colloid or >500 mL of crystalloids 
before the first blood sample was drawn.
On-scene, a first IV line was placed not to delay treatment 
of the patient. A second IV line was placed on the other side 
of the body to draw blood samples for the study. To avoid 
interference attributable to stasis, samples were drawn in the 
following sequence: (1) 9-mL serum blood (S-Monovette®; 
SARSTEDT AG & Co., Nümbrecht, Germany), (2) 9-mL 
EDTA blood (EDTA K3, S-Monovette; SARSTEDT AG & 
Co.), (3) 10-mL citrated blood (1 mL 3.2% trisodium citrate 
+ 9 mL blood, S-Monovette; SARSTEDT AG & Co.), and (4) 
1 blood gas analysis syringe (arterial blood gas sampler 1 
× 1.7 mL, 80 IU heparin, SafePICO aspirator; Radiometer 
Medical, Bronshoj, Denmark).
The same blood samples were drawn once the patient 
arrived in the ED of the University Hospital in Zurich, 
Switzerland. Blood samples from both collection periods 
were then analyzed. Several studies have demonstrated that 
blood samples remain stable during a long period of time 
at 21°C, and the analysis results are not distorted.16,17 For 
ROTEM analyses, samples are considered stable for up to 120 
minutes.18 Blood gas analyses were performed using multi-
wavelength hemoximetry (ABL 800; Radiometer Medical 
A/S, Bronshoj, Denmark). For both samples, pH, hematocrit 
(Hct), hemoglobin (Hb), lactate, glucose, base excess (BE), 
partial venous oxygen tension (pvo2), partial pressure of car-
bon dioxide (pvco2), potassium, sodium, ionized calcium, 
chloride, and bicarbonate were measured.
The ROTEM device analyzes the kinetics and qual-
ity of clot formation and clot lysis in whole blood and in 
real time. The following tests were performed: INTEM 
(ellagic acid−activated intrinsic pathway), EXTEM (tissue 
factor−triggered extrinsic pathway), FIBTEM (with plate-
let inhibitor cytochalasin D, evaluating the contribution 
of fibrinogen to clot formation), and APTEM (inhibition of 
plasmin to evaluate hyperfibrinolysis).
The following variables were determined: clotting time 
(CT), clot formation time (CFT), maximal clot firmness 
(MCF), maximal lysis (ML), and alpha-angle (α).
Two identical rotational thromboelastometry devices 
were used, equipped with 4 channels each. Both devices 
underwent complete technical revision by the manufacturer 
before starting the study. Tests ran for exactly 62 minutes. 
Further technical details of ROTEM coagulation analysis 
have been published previously by Theusinger et al.18
In the central laboratory, the following variables were deter-
mined for the 2 time points: Hb, Hct, erythrocytes, leukocytes, 
platelets, Quick test, international normalized ratio (INR), 
activated partial thromboplastin time (aPTT), fibrinogen, 
protein S100, protein S activity, protein C activity, D-dimers, 
coagulation factor V (FV), and coagulation factor XIII (FXIII) 
activity. All measurements were performed by a quality-con-
trolled International Organization for Standardization (ISO) 
17025−accredited institutional laboratory using the manufac-
turer’s reagents and according to the manufacturer’s instruc-
tions. Hb, Hct, platelet count, erythrocytes, and leukocytes 
were analyzed with the Sysmex XE-5000 (Sysmex Digitana, 
Horgen, Switzerland). Assessment of INR was determined 
by the Behring Coagulation System (BCS) XP (Siemens 
Healthcare Diagnostics GmbH, Eschborn, Germany) via use 
of the Innovin® test. aPTT was measured by BCS XP with the 
Actin® FS test. Fibrinogen (Clauss method) was measured by 
BCS XP by the use of Multifibrin U®. FXIII activity was deter-
mined by BCS XP. Protein C activity was measured using the 
protein C chromo on BCS XP. This kit measures how much pro-
tein C activity can be activated by snake venom extract (snake 
venom derivative of the Southern Copperhead, Agkistrodon 
contortrix, Protac®; Sekisui Diagnostics, LLC, Stamford, CT). 
Protein S was determined by using the Innovance® Free pro-
tein S. All aforementioned kits are manufactured by Siemens 
Healthcare Diagnostics GmbH, Eschborn, Germany. D-dimers 
were determined using the mini VIDAS® D-Dimer Exclusion 
(bioMerieux, Lyon, France) test. Protein S100 was deter-
mined by the hospital ISO 17025−accredited chemical labo-
ratory using chemical additives and Cobas® 8000 automatic 
analyzing system by Roche Diagnostics GmbH (Mannheim, 
Germany).
Other data collected at the scene and after arrival in 
the ED, were as follows: time from injury until arrival in the 
ED, age, sex, anatomic-based injury location, injury severity 
score (ISS), systolic, diastolic, and mean arterial blood pres-
sures, heart rate, transfusion requirements during the first 
24 hours after administration to the hospital, type and vol-
ume of fluids administered, use of coagulation factors, and 
30-day mortality. Preexisting diseases or treatments were 
not documented.
Polytrauma was defined as either monotrauma, multi-
trauma, or polytrauma according to Butcher and Balogh.19 
Monotrauma was defined as an injury to 1 body region and 
was considered severe if ISS >15 or ISS <15 with signifi-
cant physiological deterioration. Multitrauma was defined 
as having >1 body region injured but with an abbreviated 
injury scale not exceeding 3 in 2 regions and without the 
presence of systemic inflammatory response syndrome. 
Polytrauma injury required at least 2 body regions with an 
abbreviated injury scale >3 and with the presence of sys-
temic inflammatory response syndrome on at least 1 day 
during the first 72 hours. Severity of traumatic brain injury 
(TBI) was defined via the Glasgow Coma Scale.
The colloid used by the EMS of Zurich was 6% hydroxy-
ethyl starch (HES, Tetraspan® HES 130/0.42; B. Braun AG, 
Melsungen, Germany). In the ED of the University Hospital 
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Zurich, HES 4% gelatin (Physiogel®; B. Braun AG) also was 
used. The crystalloid used by the EMS and the University 
Hospital Zurich was a balanced lactated Ringer’s solution 
(Ringerfundin®; B. Braun AG).
Blood product usage was guided by our institutional 
blood transfusion algorithm. According to this guideline, 
the transfusion trigger for red blood cells (RBCs) was Hct 
>21%,20 fibrinogen was administered if the patient was 
bleeding and the FIBTEM showed an MCF <7 mm, FXIII 
was given when the laboratory result was <60% or when 6 
g of fibrinogen had been given, and prothrombin complex 
concentrate (PCC) was administered according to the Quick 
value.
Statistical Analyses
Floccard et al.14 presented medians and interquartile ranges 
of changes in coagulation between on-scene and the ED. We 
included INR, aPTT, fibrinogen, and FV into sample-size 
considerations. The SDs of changes were obtained as inter-
quartile range/1.35. We found that FV needed the largest 
sample size. A sample size of 44 patients will have a power 
of 90% to detect a mean change of 0.1 IU/mL when the SD 
of changes is 0.2 IU/mL, using a paired t test with a 5% 
2-sided significance level. We thus enrolled 50 patients in 
this study.
Data were analyzed using Microsoft® Excel (Microsoft 
Office 2010; Microsoft Corporation, Redmond, WA) and 
IBM® SPSS® Statistics version 20 (SPSS Inc., Chicago, IL). 
Continuous variables were summarized as mean ± SD and 
if necessary presented as median [minimum; maximum]. 
Continuous and count data were compared between on-
scene and after arrival in the ED using the Wilcoxon signed 
rank test. Ninety-five percent confidence intervals (CIs) of 
mean changes were computed based on the central-limit 
theorem. The ISS and Quick value were correlated with 
laboratory and blood gas results using Spearman rank test 
and reporting the correlation coefficients. Incidences of 
pathologic laboratory parameters were compared using the 
McNemar test. To address multiple comparisons, P values 
of ≤0.01 were considered significant.
RESULTS
Patient Characteristics
Fifty patients were included in this study. Six patients (12%) 
died during the first 30 days. The mean age was 44 ± 21 
years, and 37 patients (74%) were male. The mean body 
weight was 73 ± 14 kg, height 173 ± 7 cm, and body mass 
index 24.4 ± 4.1. All patients experienced blunt trauma. 
Fourteen patients (28%) were classified as monotrauma, 
19 patients (38%) as multitrauma, and 17 patients (34%) as 
polytrauma. Forty-four patients sustained a TBI (18 mild, 
10 moderate, and 16 severe). In 14 (82%) of the polytrauma 
patients, a TBI was part of the injury (Table 1). The mean 
ISS on arrival at the ED was 25 ± 22 with a median [mini-
mum; maximum] value of 17 [4; 75]. The time from injury to 
arrival in the ED was 50 ± 16 (45[23; 83]) minutes. On-scene, 
systolic, diastolic, and mean arterial blood pressures were 
127 ± 30, 80 ± 14, and 95 ± 18 mm Hg, respectively. Heart 
rate on-scene was 85 ± 21 beats per minute and stayed the 
same until arrival in the ED (88 ± 28 beats per minute). In 
the ED, systolic blood pressure was 126 ± 28 mm Hg, dia-
stolic was lower (72 ± 18 mm Hg), and mean arterial blood 
pressure was significantly lower compared with on-scene 
with 90 ± 20 mm Hg (P < 0.001), respectively (Table 2).
Volume Management
In all patients, blood samples were drawn before any col-
loid and <500 mL crystalloids were given. Until arrival in 
the ED, all 50 patients received crystalloids, and 8 patients 
received HES as well. On average, patients received 542 ± 
432 mL of crystalloids and 79 ± 222 mL of colloids between 
on-scene and arrival in the ED and before the second blood 
sample was drawn in the ED. In the ED and during the first 
24 hours of hospitalization, 48 patients received crystalloids 
and 19 patients additionally received colloids (Table 2). 
More fluids were given in the ED (1076 ± 1294 mL [P = 0.007] 
Table 1.  Patient Characteristics and Injury Data
Characteristics All patients (n = 50)
Age, y 44 ± 21 (42 [17; 94])
Male sex 37 (74%)
BMI, kg/m2 24.4 ± 4.1 (23.0 [19.2; 35.5])
Injury
  Monotrauma/multitrauma/
polytrauma
19/14/17
  Monotrauma with TBI 17
  Multitrauma with TBI 13
  Polytrauma with TBI 14
  TBI 44 (88%)
  TBI (mild/moderate/severe) 18/10/16
  ISS 25 ± 22 (17 [4; 75])
ISS ≥16 29 (58%)
ISS = 75 6 (12%)
Time from on-scene to ED; min 50 ± 16 (45 [23; 83])
Values are expressed as mean ± SD (median [minimum; maximum]) or 
number (%).
BMI = body mass index; TBI = traumatic brain injury; ISS = injury severity 
score; on-scene = period from injury to arrival at the emergency department; 
ED = emergency department.
Table 2.  Procedural Data On-Scene and After 
Arrival ED
Characteristics 
values
On-scene  
(n)
ED + first 24 hours 
(n) P
BPsyst, mm Hg 127 ± 30 126 ± 28 0.30
BPdiast, mm Hg 80 ± 14 72 ± 17 0.012
MAP, mm Hg 95 ± 18 90 ± 20 ≤0.001
Heart rate, bpm 85 ± 21 88 ± 28 0.76
Crystalloidsa, mL 542 ± 432 (50) 1076 ± 1294 (48) 0.007
Colloidsa, mL 79 ± 222 (8) 454 ± 995 (19) ≤0.001
RBC, units 0 17 ± 8 (3)
FFP, units 0 9 ± 2 (2)
Platelets, units 0 3 ± 2 (3)
Tranexamic acid, g 0 1.2 ± 0.4 (8)
PCC, IU 0 2000 ± 817 (3)
Fibrinogen, g 0 8.9 ± 4.8 (7)
Factor XIII, IU 0 2813 ± 2049 (4)
Values are expressed as mean ± SD and n (number of patients treated), 
volumes infused refer between on-scene and arrival in the ED.
ED = emergency department; BPsyst = systolic blood pressure; BPdiast = 
diastolic blood pressure; MAP = mean arterial blood pressure; bpm = beats 
per minute; RBC = red blood cell; FFP = fresh-frozen plasma; PCC = human 
prothrombin complex, which includes factor II, VII, IX, X, activated protein C, 
and protein S; IU = international unit; on-scene = period from injury to arrival 
at the emergency department. 
aAdministered after on-scene blood sample withdrawn.
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crystalloids and 454 ± 985 mL [P < 0.001] colloids) than dur-
ing the period between on-scene and arrival in the ED.
Blood Products
No blood products or coagulation factors were administered 
between the scene of injury and arrival in the ED (Table 2). 
In the ED, RBCs, fresh-frozen plasma, and platelets were 
given in 3 (6%), 2 (4%), and 3 (6%) patients, respectively, 
after the second blood sample was drawn. Tranexamic acid 
(Cyklokapron®; Pfizer Corporation Austria GmbH, Vienna, 
Austria) was administered in 8 patients (16%). Four-factor 
(II, VII, IX, and X) PCC (Beriplex® P/N; CSL Behring AG, 
Bern, Switzerland) was given in 3 patients (6%). Seven 
patients (14%) received fibrinogen (Haemocomplettan®; CSL 
Behring AG) and in 4 patients (8%), FXIII (Fibrogammin®; 
CSL Behring AG) was given. Data presented are the mean ± 
SD of factors or blood products of patients having received 
any of those products. FXIII was given with a mean of 2813 ± 
2049 IU with a range of 1250 to 6250 IU. Fibrinogen 8.9 ± 4.8 
g was given with a range of 4 to 18 g. Four-factor PCC was 
given with a mean of 2000 ± 817 IU with a range of 1000 to 
3000 IU. Tranexamic acid was administered with 1.2 ± 0.4 g 
with a range of 1 to 2 g.
In the first 24 hours (ED, operating room, and intensive 
care unit), the mean ± SD (range) RBC use was 17 ± 8 (6–26) 
units, platelet use was 3 ± 2 (1–6) units, and fresh-frozen 
plasma use was 9 ± 2 (7–11) units.
Blood Gas Analysis
Significant changes (all P ≤ 0.005) between on-scene and 
the ED were observed for Pvo2, sodium, glucose, and lac-
tate. Twenty-four patients had a pH <7.34 on-scene, and in 
2 patients, the pH was <7.20. In the ED, a pH <7.34 was 
measured in 27 patients and a pH <7.20 in 1 patient. Lactate 
values above the normal upper threshold of 1.6 mmol/L 
were measured in 45 patients on-scene and in 31 patients 
in the ED. Lactate values >4 mmol/L were measured in 11 
patients on-scene and in 5 patients in the ED. Details are 
shown in Table 3. The pH (r = −0.27; P = 0.05, not significant), 
HCO3− (r = −0.30; P = 0.032, not significant), and BE values 
(r  =  −0.32; P  =  0.022, not significant) measured on-scene 
may have correlated weakly with the ISS, but the correla-
tion increased slightly after arrival in the ED (pH [r = −0.40; 
P = 0.004], HCO3− [r = −0.32; P = 0.024, not significant], and 
BE values [r = −0.41; P = 0.003]). After arrival, the ED lactate 
values may have correlated weakly with the ISS (r = 0.29; 
P  =  0.038, not significant). Whereas a possible weak cor-
relation for pH and lactate was found on-scene (r  =  0.36; 
P = 0.011, not significant), the correlation was moderate and 
significant in the ED (r = 0.58; P < 0.001). Lactate and aPTT 
did not correlate on-scene (r = 0.06; P = 0.69, not significant) 
but may have in the ED (r = 0.42; P < 0.001); the same results 
were found for pH and aPTT (r = 0.05; P = 0.72, not signifi-
cant on-scene and r = 0.51; P < 0.001 in the ED).
Laboratory Results
On-Scene
Laboratory values below the lower limit of the normal range 
were measured for platelets in 3 (6%), fibrinogen in 3 (6%), 
FV in 2 (4%), FXIII activity in 3 (6%), protein C activity in 5 
(10%), and protein S in 6 patients (12%). Thirteen patients 
(26%) had a Quick value, and 27 (54 %) presented an aPTT 
below the normal range (Table 4).
Laboratory values above the upper limit of the normal 
range were measured for platelets in 2 (4%), fibrinogen in 
2 (4%), FV in 3 (6%), FXIII activity in 8 (16%), D-dimer >0.5 
mg/L in 44 (88%), D-dimer >4 mg/L in 12 (24%), protein C 
activity in 3 (6%), protein S in 4 (8%), and protein S100 in 
49 patients (98%) (Table 4). Quick values, aPTT, fibrinogen, 
FV, and FXIII activity level did not correlate with the ISS. A 
significant correlation with ISS was found for Hb (r = −0.37; 
P  =  0.008), protein S100 (r  =  0.67; P < 0.001), D-dimers 
(r  =  0.72; P < 0.001), and protein S (r  =  −0.41; P  =  0.003). 
Fibrinogen (r = 0.41; P < 0.001), FV (r = 0.68; P < 0.001), FXIII 
activity (r = 0.41; P = 0.003), protein C activity (r = 0.45; P 
< 0.001), and protein S (r = 0.40; P = 0.004) may have sig-
nificantly correlated with the Quick value. The only value 
that may have had weak evidence for a correlation with the 
aPTT was FV (r = −0.33; P = 0.018, not significant).
In the ED
The numbers of patients having laboratory values below 
the lower limit of the normal range increased for platelets 
in 9 (18%; P = 0.013, not significant), fibrinogen in 5 (10%; 
P  =  0.16, not significant), protein C activity in 9 (18%; 
P = 0.044, not significant), and protein S in 9 patients (18%; 
P  =  0.083, not significant). Quick value and aPTT values 
Table 3.  Changes of Blood Gas Analysis Data Between On-Scene and After Arrival ED
Characteristics On-scene (n = 50) ED (n = 50) Difference (95% CI) P
pH 7.32 ± 0.06 7.32 ± 0.08 0.00 (−0.02 to 0.02) 0.98
Pvco2, kPa 6.12 ± 0.95 6.04 ± 1.73 −0.77 (−2.55 to 1.01) 0.15
Pvo2, kPa 8.80 ± 6.64 17.06 ± 16.30 8.27 (3.71 to 12.83) 0.003
HCO3, mmol/L 22.94 ± 2.97 22.27 ± 3.46 0.67 (−0.15 to 1.49) 0.052
BE, mmol/L −2.78 ± 3.26 −3.31 ± 3.96 0.53 (−0.26 to 1.31) 0.21
Anion gap 7.73 ± 3.55 6.97 ± 3.07 0.76 (−0.25 to 1.78) 0.018
K+, mmol/L 3.87 ± 0.65 3.82 ± 0.56 0.06 (−0.14 to 0.25) 0.82
Na+, mmol/L 138.28 ± 4.22 137.12 ± 3.89 1.16 (0.37 to 1.95) 0.002
Ca++, mmol/L 1.17 ± 0.08 1.16 ± 0.14 0.01 (−0.03 to 0.04) 0.66
Cl−, mmol/L 107.44 ± 4.25 107.74 ± 3.58 −0.30 (−1.02 to 0.42) 0.32
Glu, mmol/L 7.63 ± 2.91 7.12 ± 2.64 0.51 (0.10 to 0.92) 0.004
Lct, mmol/L 3.08 ± 1.59 2.29 ± 1.60 0.79 (0.36 to 1.21) ≤0.001
Values are expressed as mean ± SD.
ED = emergency department; CI = confidence interval; Pvco2 = venous carbon dioxide tension; Pvo2 = venous oxygen tension; HCO3 = bicarbonate; BE = base excess; 
K+ = potassium; Na+ = sodium; Ca++ = calcium; Cl− = chloride; Glu = glucose; Lct = lactate; on-scene = period from injury to arrival at the emergency department. 
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below the lower level of the normal range were found in 
12 (P = 0.32, not significant) and 18 (P = 0.013, not signifi-
cant) patients, respectively. The number of patients having 
FXIII activity below the normal range and D-dimer levels 
>4 mg/L increased to 11 (P  =  0.083, not significant) and 
20 (P  =  0.004) patients, respectively. For other measured 
variables, the number of patients having laboratory val-
ues above the upper limit of the normal range decreased 
for fibrinogen to 1 (2%; P = 0.32, not significant), protein C 
activity to 2 (4%; P = 0.32, not significant), and protein S to 
2 patients (4%; P = 0.16, not significant). Protein S100 levels 
were increased in all patients and did not change.
Table  5 presents the significant changes in coagulation 
measurements between on-scene and arrival in the ED. 
D-dimers increased; Hb, Hct, and platelets decreased; and 
protein C activity, protein S, fibrinogen, FV, and FXIII activ-
ity, and protein S100 decreased. There was a trend for an 
increase of aPTT (P = 0.04, not significant). Compared with 
on-scene, no changes in Quick value, INR, and leukocytes 
were found (Table 5). The Hb (r  =  −053; P < 0.001), Hct 
(r = −053; P < 0.001), protein S100 (r = 0.69; P < 0.001), D-dimer 
(r = 0.72; P < 0.001), and protein S (r = −0.54; P < 0.001) were 
significantly correlated with the ISS. There may have been 
a weak correlation of FXIII activity (r = −0.34; P = 0.014, not 
significant) with ISS.
The correlations of fibrinogen (r  =  0.51; P < 0.001), FV 
(r = 0.79; P < 0.001), FXIII activity (r = 0.54; P < 0.001), protein 
C activity (r = 0.57; P < 0.001), protein S (r = 0.45; P = 0.001), 
and the D-dimer (r  =  0.32; P  =  0.025, not significant) with 
the Quick value increased compared with those on-scene. 
Besides FV (r = −0.40; P = 0.004), protein C activity (r = −0.35; 
P = 0.012, not significant) and protein S (r = −0.33; P = 0.018, 
not significant) may have correlated weakly with the aPTT.
ROTEM
Changes in ROTEM variables between on-scene and after 
arrival the ED are shown in Table 6.
On-Scene
In 4 patients (8%), ROTEM variables (CT, CFT, and MCF) 
were below the lower limit of the normal range. In 1 patient 
(patient 25), an MCF above the normal range was measured 
for FIBTEM of the ROTEM. In 5 patients (10%), ML was 
>15%. All other ROTEM variables measured on-scene were 
within the normal range.
In the ED
When compared with on-scene, significantly more patients 
(n = 18, 36%) had ROTEM variables below the lower limit 
of the normal range (P  =  0.002). In 1 patient (patient 25), 
an MCF above the normal range was measured for FIBTEM 
of the ROTEM. Compared with on-scene, an additional 3 
patients (6%) had ML >15% upon arrival to the ED. Table 6 
presents the significant changes in ROTEM measurements 
performed between on-scene and the ED. For EXTEM, 
INTEM, and APTEM, CT and CFT increased significantly, 
whereas MCF and angle α decreased significantly. For 
FIBTEM, CT increased significantly, MCF decreased signifi-
cantly, and ML was interestingly lower in the ED.
Post hoc analysis revealed that exclusion of 3 patients 
who needed RBC transfusion did not significantly influ-
ence any measured variables (hemodynamics, ISS blood gas 
analysis, laboratory results, and point-of-care results) either 
on-scene or after arrival in the ED.
DISCUSSION
The main findings early after injury are (1) Quick values 
were pathologic in at least 13% of the patients (95% CI, 
13%–35%) and aPTT in at least 26% (95% CI, 26%–52%), but 
only aPTT increased significantly after admission in the ED; 
(2) D-dimer levels were increased in 88% (44 of 50 patients 
D-dimer >0.5) of the patients and increased significantly 
until arrival at the ED; (3) Hb, platelet, fibrinogen, FV and 
FXIII activity, protein C activity, and protein S100 values 
were significantly decreased from on-scene to ED arrival 
(Table 5); (4) ROTEM variables were abnormal in 8% of the 
patients (reduced MCF) on-scene but in 36% of patients 
after arrival in the ED; (5) protein S100 levels were increased 
in 98% of the patients on-scene but decreased signifi-
cantly until admission in the ED (4.14 ± 1.49 to 2.37 ± 4.66; 
P < 0.001); and (6) on-scene 70% of the patients developed 
lactate levels above the upper limit of the normal range, and 
half of these patients presented with lactic acidosis.
Table 4.  Pathologic Laboratory Parameters 
On-Scene and After Arrival in the ED
Characteristics
On-scene 
(n)
ED 
(n)
Total changes,  
n (%), 95% CI P
Hb, <12 g/dL 5 19 14 (28), 17%–42% <0.001
Hct, <36% 6 24 18 (36), 24%–50% <0.001
Platelets <143 g/L 3 9 6 (12), 6%–24% 0.014
Leukocytes >9.6 g/L 21 21 14 (28), 17%–42% 1.0
Quick value <70% 13 12 11 (22), 13%–35% 0.76
INR >1.3 2 3 3 (6), 2%–16% 0.564
aPTT
  <26 s 27 18 19 (38), 26%–52% 0.039
  >36 s 0 1 3 (6), 2%–16% 0.083
FBG
  <1.5 g/dL 3 5 4 (8), 3%–19% 0.32
  >4.0 g/dL 2 1 1 (2), 1%–10% 0.32
FV
  >150% 3 13 10 (20), 11%–33% 0.16
  <50% 2 3 1 (2), 0%–10% 0.32
FXIII
  >120% 8 3 5 (10), 4%–21% 0.025
  <70% 3 10 7 (14), 7%–26% 0.008
D-dimer
  >0.5 44 44 2 (4), 1%–13% 1.0
  >4.0 18 24 8 (16), 8%–29% 0.034
Protein C
  >120% 3 2 1 (2), 0%–10% 0.32
  <60% 4 9 7 (14), 7%–26% 0.059
Protein S
  >120% 4 2 4 (8), 3%–19% 0.32
  <50% 6 9 7 (14), 7%–26% 0.26
Protein S100 49 50 1 (2), 0%–10% 0.32
Incidences are expressed as numbers, and total changes between both 
time points (patients who changed from pathologic to normal or from normal 
to pathological values) are expressed as numbers with percent and 95% 
Wilson CIs. P values correspond to McNemar test between time points. Total 
changes are means that change in a laboratory parameter in comparison 
with the measurement on-scene and in the ED. This was considered in 
both directions. This ensures that pathologic laboratory values measured 
on-scene can be normalized in the ED and vice versa.
ED = emergency department; on-scene = period from injury to arrival at the 
emergency department; ; CI = confidence interval; Hb = hemoglobin; Hct = 
hematocrit; INR = international normalized ratio; aPTT = activated prothrombin 
time; FBG = fibrinogen; FV = coagulation factor V; FXIII = coagulation factor XIII.
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Data describing changes in the coagulation status of 
patients are sparse in the early period after trauma. Only 1 
study has performed standard coagulation tests and mea-
surements of FV, protein C activity, and antithrombin III 
on-scene and after admission in the ED of the hospital.14 
Floccard et al.14 found abnormal coagulation in 56% of their 
patients on-scene and in 60% on hospital admission. The 
on-scene coagulopathy was spontaneously normalized in 2 
patients, whereas others had the same or a poorer coagu-
lopathy status, which are quite similar findings to ours.
In our study, blood samples were taken directly at the 
location of the injury and as soon as possible after admis-
sion to the ED. In addition, we evaluated coagulation by 
using several approaches: standard and advanced labora-
tory coagulation tests, ROTEM, blood gas analysis, and pro-
tein S100 as a brain trauma marker.
Several studies have shown that systemic hypoperfu-
sion itself plays a central role in the pathogenesis of early 
traumatic coagulopathy.21,22 A dose-dependent associa-
tion between the degree of coagulopathy after admission 
to the ED measured with the Quick value and aPTT, and 
the severity of tissue hypoperfusion has been reported.23,24 
White et al.25 demonstrated in a swine model that traumatic 
shock itself significantly reduced the fibrinogen concentra-
tion and the clot strength as measured by the maximum 
amplitude of thromboelastography. The high proportion 
of patients on-scene with metabolic acidosis and lactate 
concentrations above the upper limit of the normal range 
in this study supports the suggestion that significant hypo-
perfusion states are present very early after severe trauma. 
Nearly half (n = 23; 46%) of these patients initially devel-
oped lactic acidosis (pH <7.34, lactate >1.6 mmol/L) as the 
result of extensive hypoperfusion of tissues. Six of these 
patients demonstrated a hypocoagulable state (INR >1.2, 
Quick value <70%). The other 17 patients still had coagula-
tion variables within the normal range. Another 7 patients 
were hypocoagulable and had high lactate levels with a pH 
still in the normal range. Even though lactate concentrations 
decreased after initial intravascular volume resuscitation 
until reaching the ED, the degree of acidosis remained the 
Table 5.  Changes in Laboratory Parameters Between On-Scene and After Arrival ED
Characteristics On-scene ED Difference (95% CI) P
Hb, g/dL 13.92 ± 1.82 12.27 ± 2.01 1.55 (1.13 to 1.97) ≤0.001
Hct, % 39.91 ± 5.01 35.62 ± 5.47 4.59 (3.34 to 5.84) ≤0.001
Platelets, ×109/L 259.26 ± 84.18 213.14 ± 75.18 46.12 (32.43 to 59.82) ≤0.001
Leukocytes, g/L 10.38 ± 4.86 10.43 ± 4.87 −0.05 (−1.11 to 1.02) 0.99
Quick value, % 81.14 ± 17.70 80.62 ± 18.31 0.52 (−3.49 to 4.53) 0.43
INR 1.13 ± 0.17 1.16 ± 0.27 −0.03 (−0.07 to 0.02) 0.45
aPTT, s 26.26 ± 4.09 29.46 ± 16.82 −3.20 (−7.41 to 1.01) 0.041
FBG, g/L 2.53 ± 0.90 2.10 ± 0.74 0.43 (0.29 to 0.56) ≤0.001
FV, % 107.64 ± 32.09 89.88 ± 29.28 17.76 (11.76 to 23.76) ≤0.001
FXIII, % 110.98 ± 24.83 90.54 ± 26.56 20.44 (15.63 to 25.25) ≤0.001
D-dimer, ng/L 4.80 ± 5.44 7.43 ± 8.44 2.63 (1.18 to 4.07) ≤0.001
Protein C activity, % 94.68 ± 23.65 80.30 ± 22.39 14.38 (9.69 to 19.07) ≤0.001
Protein S100, μg/L 4.14 ± 1.49 2.37 ± 4.66 7.80 (3.78 to 11.82) ≤0.001
Values are expressed as mean ± SD.
ED = emergency department; CI = confidence interval; Hb = hemoglobin; Hct = hematocrit; INR = international normalized ratio; aPTT = activated prothrombin 
time; FBG = fibrinogen; FV = coagulation factor V; FXIII = coagulation factor XIII; on-scene = period from injury to arrival at the emergency department.
Table 6.  Changes in ROTEM Parameters Between On-Scene and After Arrival ED
Characteristics On-scene ED Difference (95% CI) P
EXTEM CT, s 61 ± 21 75 ± 28 13.72 (9.05 to 18.39) ≤0.001
CFT, s 124 ± 40 161 ± 104 36.82 (12.11 to 61.53) ≤0.001
MCF, mm 58 ± 7 50 ± 9 7.60 (6.47 to 8.73) ≤0.001
Angle α in, degrees 68 ± 7 59 ± 9 8.90 (7.31 to 10.49) ≤0.001
ML, % 9 ± 20 6 ± 6 3.14 (−1.84 to 8.12) 0.055
INTEM CT, s 137 ± 29 162 ± 41 25.76 (18.32 to 33.20) ≤0.001
CFT, s 97 ± 40 133 ± 101 36.66 (12.11 to 61.21) ≤0.001
MCF, mm 58 ± 9 50 ± 10 7.26 (5.99 to 8.53) ≤0.001
Angle α, degrees 73 ± 5 64 ± 10 9.14 (7.25 to 11.04) ≤0.001
ML, % 8 ± 18 6 ± 6 2.84 (2.25 to 7.93) 0.23
APTEM CT, s 64 ± 16 79 ± 41 15.62 (5.26 to 25.98) ≤0.001
CFT, s 126 ± 43 178 ± 161 51.24 (10.63 to 91.85) ≤0.001
MCF, mm 57 ± 6 50 ± 8 7.46 (6.11 to 8.81) ≤0.001
Angle α, degrees 66 ± 6 57 ± 10 8.96 (7.22 to 10.70) ≤0.001
ML, % 4 ± 3 4 ± 4 −0.70 (−1.60 to 0.20) 0.084
FIBTEM CT, s 127 ± 502 175 ± 560 −48.30 (−122.28 to 25.68) ≤0.001
MCF, mm 14 ± 5 11 ± 5 3.22 (2.72 to 3.73) ≤0.001
ML, % 7 ± 20 6 ± 10 0.25 (−4.39 to 4.88) 0.017
Values are expressed as mean ± SD.
ROTEM = thromboelastometry; ED = emergency department; CI = confidence interval; EXTEM = tissue factor activation; CT = coagulation time (in second); CFT = 
clot formation time (in seconds); MCF = maximum clot firmness (in millimeter); ML = maximal lysis (in millimeters); INTEM = contact activation; α = alpha angle; 
APTEM = tissue factor activation combined with aprotinin; FIBTEM = tissue factor activation combined with platelet inhibition; on-scene = period from injury to 
arrival at the emergency department. 
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same. A decrease of lactate and remaining acidosis might 
be explained by only limited volume replacement in the 
initial period between on-scene and arrival the ED, which 
is in agreement with previously reported results and rec-
ommendations in the latest update of the European trauma 
treatment guidelines.11,26,27 Although acidosis itself may 
affect coagulation, adverse effects of acidosis on extrinsic 
and intrinsic coagulation pathways and on platelet function 
are not generally seen until the pH decreases <7.2.28 In our 
study, only 2 patients had a pH <7.2 and both died. These 
patients developed massive hemorrhage due first to the 
major injury itself and second to the disturbed coagulation 
system.
At the scene of trauma, we found a Quick value <70% in 
26%, a shortened aPTT in 54%, and an increased D-dimer in 
88% of patients. In one-quarter of the patients, the D-dimer 
concentration was >4 mg/L. The combination of normal 
Quick value, decreased aPTT, and pathologic high levels of 
D-dimer suggests a massive activation of coagulation fac-
tors (hypercoagulable) leading to their consumption and 
simultaneously to an activated fibrinolytic system early 
after trauma. ROTEM analysis found an ML >15% in only 8 
patients, showing a systemic hyperfibrinolysis, whereas our 
other results suggest a local hyperfibrinolysis/fibrinolysis 
that seems to play a role in the early phase of trauma. The 
shortened aPTT might be explained by a sudden increase of 
FVIII in the context of a severe trauma.
Floccard et al.14 reported similar results but used the 
scoring system proposed by the International Society on 
Thrombosis and Haemostasis. They reported that 50% of 
patients on-scene and 60% of the patients after arrival to 
the ED experienced trauma-associated coagulopathy and 
that D-dimer levels were increased both on-scene and 
after admission to the ED. In our investigation, the platelet 
count, aPTT, fibrinogen, FV, FXIII activity, protein C activity, 
and protein S on-scene were in the normal range and thus 
gave no indication of the current coagulation state during 
trauma-associated bleeding. This observation is in agree-
ment with previous findings that procoagulant coagula-
tion factors are critically reduced in the late stages of blood 
loss.29,30 Mittermayr et al.29 and Innerhofer30 hypothesized 
that most factors are needed at low concentrations and short 
half-life times. These hypotheses, however, are based only 
on investigating the procoagulant and anticoagulant coagu-
lation factors after admission to the hospital. Interestingly, 
in our study, fibrinogen, FV, FXIII activity, protein C activ-
ity, and protein S all decreased and aPTT increased between 
on-scene and the ED. The decrease in coagulation factors is 
unlikely to have been attributable to dilutional coagulopa-
thy because only small volumes of crystalloids (1076 ± 1294 
mL) and in particular colloids (454 ± 995 mL) were infused 
between on-scene and arrival the ED. The use of colloids 
such as HES further predisposes to a coagulopathy which is 
difficult to reverse.31 No or little volume (no colloids) given 
before the first blood drawn is unlikely to have influenced 
the results of the measurement of this study because the 
amount of colloids given was 79 ± 222 mL and the amount of 
crystalloids 542 ± 432 mL before the second blood drawn in 
the ED are considered low. One possible explanation is that 
trauma induces a massive coagulation response, including 
increased protein C activity, which thus leads to a decrease 
of fibrinogen, FV, FXIII activity, protein C activity and pro-
tein S, and an increased aPTT. Because we measured protein 
C activity based on the not yet protein C activity, our results 
presented in Table 4 are correct because less unactivated pro-
tein C is available in the late phase of trauma due to earlier 
activation. Data from the German Trauma Registry of 8724 
patients show a clear relationship between early coagulopa-
thy and the volume of fluids administered.12 The registry 
reported an incidence of early coagulopathy at >40%/>50% 
and >70% with fluid volumes of >2000, 3000, and 4000 mL, 
respectively.12 In contrast, a retrospective study of 1088 trau-
matized patients by Brohi et al.27 demonstrated that the inci-
dence of early coagulopathy was not related to preclinical 
fluid administration but clearly associated with the severity 
of injury. This shows that there are actually 2 completely 
opposite ways to explain coagulopathy in trauma patients.
In addition to standard laboratory evaluation, our study 
included ROTEM measurements both on-scene and after 
arrival in the ED. On-scene in 8% of the patients, the MCF of 
the ROTEM was reduced, presenting reduced clot strength 
and 10% presented an ML >16%. After arrival in the ED, 36% 
of the patients had abnormal ROTEM parameters, including 
increases in CT and CFT of EXTEM, INTEM, and APTEM and 
decreases in angle α and MCF compared with on-scene values. 
In addition, FIBTEM CT was prolonged and the MCF reduced. 
These data suggest an early deficiency or loss of activity of 
coagulation factors such as fibrinogen, FXIII, and platelets and 
were supported by simultaneously determined platelet count 
and changes in FV, FXIII activity, protein C activity, and protein 
S. Davenport et al.32 hypothesized that traumatic coagulopathy 
is characterized by reduction in clot strength and has a specific 
thromboelastometric signature, which can be diagnosed by the 
clot amplitude at 5 minutes. Although our study was too small 
to test this possibility, reduced clot strength was seen in more 
than one-third of the patients in the ED. Another reason for 
the development of impaired clot formation measured with 
ROTEM might be a dilutional coagulopathy caused by intra-
vascular volume resuscitation during patient transport to the 
ED. In an in vitro study, Haas et al.33 reported significant wors-
ened clot formation after diluting blood samples by using 60% 
lactated Ringer’s solution. In this investigation, the crystalloid 
volume replacement was only 542 ± 432 mL, and colloid was 
only given to 8 patients. We thus believe it unlikely that the 
worsened coagulation and clot formation were caused by dilu-
tion. In cases in which clearly pathological values of ROTEM 
are identified, early treatment as suggested by the European 
Trauma Guidelines26 might be useful, and administration of 
factor concentrates has been suggested to treat traumatic coag-
ulopathy by Theusinger et al.20
Limitations
Some limitation of this study should be noted. The study 
sample size was small. Hence, subgroup analysis for differ-
ent ISS classes or for patients with significant hypoperfusion 
states was not performed because of insufficient power. For 
ethical reasons, blood samples on-scene and in the ED were 
always performed without disturbing life-sustaining treat-
ment. Therefore, it cannot be ensured that blood samples 
were drawn before the first dose of volume replacement. In 
addition, samples for blood gas analysis were performed 
from a second venous access site and not cooled on ice during 
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transportation to the ED. However, several studies have dem-
onstrated that blood samples remain stable over a long period 
of time at 21°C temperature, so we do not believe these values 
distort our analysis.16,17 We also did not measure body tem-
perature of our patients on arrival to the ED. Hypothermia 
may have also altered our measurement of coagulation status. 
Blood loss was neither calculated nor was it estimated because 
the data were not available for the days after trauma. In only 
8 patients, ML >15% indicated systemic hyperfibrinolysis. 
These results might suggest that in an early phase of trauma, 
hyperfibrinolysis could be a local phenomenon because high 
D-dimers show the presence of fibrinogen split products.
CONCLUSIONS
In the urban setting with transport times <1 hour, coagula-
tion values measured on arrival to the ED change drasti-
cally from those measured at the scene of trauma. On-scene 
measurements thus do not provide clinically relevant infor-
mation that leads to an acute specific laboratory variable-
based therapeutic intervention in most trauma patients. 
For 1 hour after injury, significant activation and consump-
tion of fibrinogen, FV, FXIII, protein C activity, and protein 
S were observed. Markers such as increasing D-dimers 
indicate a progressive fibrinolysis even if not shown by 
an increased ML in ROTEM. Routine coagulation tests 
may not indicate the diagnosis of ongoing coagulopathy. 
Thromboelastometry promises to be a useful tool for early 
detection of traumatic coagulopathy. E
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